摘要
目的探究外周血中性粒细胞与淋巴细胞比值(NLR)以及血小板与淋巴细胞比值(PLR)在非小细胞肺癌(NSCLC)患者化疗疗效及预后中的评估价值。方法选择2019年3月—2021年6月我院收治87例NSCLC患者各项资料予以回顾性分析,患者在化疗治疗前均测定外周血中性粒细胞、淋巴细胞、血小板,并计算NLR与PLR,评估患者疗效及预后,分析NLR与PLR在患者化疗疗效及预后中的评估价值。结果NLR、PLR水平与患者吸烟史、肿瘤分期、是否出现淋巴结转移有关(P<0.05);患者接受两个周期化疗后治疗有效率为71.26%,有效组患者NLR与PLR水平显著低于无效组(P<0.05);受试者工作特征曲线显示,NLR、PLR及两者联合用于评估患者化疗疗效曲线下面积分别为0.859、0.785、0.926;患者预后不良发生率为32.18%,单因素与多元Logistic回归分析显示分化程度、PLR、NLR与患者预后有关(P<0.05)。结论外周血NLR、PLR与患者多项临床特征有关,不仅可用于患者评估患者化疗疗效,还与患者预后关系密切。
Objective To investigate the value of peripheral blood neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)in evaluating chemotherapy response and prognosis of patients with non-small cell lung cancer(NSCLC).Methods The data of 87 patients with NSCLC admitted to the hospital from March 2019 to June 2021 were retrospectively analyzed.Peripheral blood neutrophils,lymphocytes,and platelets were measured before chemotherapy to calculate NLR and PLR.The efficacy and prognosis were evaluated.The value of NLR and PLR in evaluating chemotherapy response and the prognosis was analyzed.Results NLR and PLR were related to smoking history,tumor stage,and lymph node metastasis(P<0.05).The effective rate was 71.26%after 2 cycles of chemotherapy,and NLR and PLR in the effective group were significantly lower than those in the ineffective group(P<0.05).The receiver operating characteristic curve showed that the areas under the curve of NLR,PLR alone and in combination to evaluate chemotherapy response were 0.859,0.785,and 0.926,respectively.The incidence of poor prognosis was 32.18%.Univariate analysis and multivariate logistic regression analysis showed that differentiation degree,PLR and NLR were related to the prognosis(P<0.05).Conclusion Peripheral blood NLR and PLR are related to many clinical characteristics of patients with NSCLC.The two can be used to evaluate chemotherapy response and the prognosis.
作者
靳璐璐
黄景慧
王明明
张梦梦
谢瑞玉
JIN Lulu;HUANG Jinghui;WANG Mingming;ZHANG Mengmeng;XIE Ruiyu(Department of Laboratory Medicine,Chuzhou Hospital Affiliated to Anhui Medical University,Chuzhou First People′s Hospital,Chuzhou 239000,Anhui,China;Department of Oncology,Chuzhou Hospital Affiliated to Anhui Medical University,Chuzhou First People′s Hospital,Chuzhou 239000,Anhui,China)
出处
《西部医学》
2023年第9期1310-1314,共5页
Medical Journal of West China
基金
安徽省自然科学基金项目(1808085J10)。
关键词
中性粒细胞/淋巴细胞
血小板/淋巴细胞
非小细胞肺癌
化疗疗效
预后
Neutrophil-to-lymphocyte ratio
Platelet-to-lymphocyte ratio
Non-small cell lung cancer
Chemotherapy response
Prognosis
